Study guide

11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD)

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD)

Key Takeaways Explain This Topic AI

USP <795> establishes legal standards for Non-Sterile Compounded Preparations (CNSPs) across community, hospital, and institutional compounding settings.

Master Formulation Records (MFR) serve as the pre-established compounding protocol, while Compounding Records (CR) document the step-by-step execution of an individual batch or prescription.

Nonaqueous formulations (capsules, tablets, nonaqueous ointments/suppositories) have a maximum default BUD of 180 days (6 months) when stored at controlled room temperature.

Water-containing oral formulations (solutions, suspensions, oral syrups) have a maximum default BUD of 14 days when stored under refrigeration (2°C to 8°C).

Water-containing topical, dermal, and mucosal liquid or semisolid formulations have a maximum default BUD of 30 days stored at controlled room temperature.

Last updated: July 2026

11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD)

MPJE Core Concept: USP General Chapter <795> sets enforceable quality assurance standards for Compounded Non-Sterile Preparations (CNSPs). Compounding pharmacists must distinguish between Master Formulation Records and Compounding Records and strictly enforce federal Beyond-Use Dating (BUD) caps based on water activity and storage conditions.

Scope and Categorization of USP <795>

USP <795> applies to all persons who prepare compounded non-sterile preparations in healthcare settings, including community pharmacies, hospital pharmacies, and outpatient clinics. The chapter defines compounding as the process of combining, admixing, diluting, pooling, reconstituting (other than according to manufacturer instructions), or otherwise altering a drug or bulk substance to create a non-sterile preparation.

Compounding Complexity Levels

USP <795> classifies non-sterile compounding into three levels of complexity:

Simple Compounding: Preparing a formulation that has an official USP monograph or is derived from a peer-reviewed commercial study specifying exact ingredients, quantities, procedure, and stability data (e.g., Capped reconstitutions with additives, simple topical ointments).

Moderate Compounding: Preparing a formulation that requires special calculations, mixing ingredients where stability data for the specific combination is missing, or compounding transdermal gels.

Complex Compounding: Preparing formulations requiring specialized training, complex calculations, specialized equipment, or physical mechanisms (e.g., modified-release preparations, suppositories with complex lipid bases, troches).

Documentation Requirements: MFR vs. CR

Complete, traceable documentation is mandatory under USP <795>. Pharmacists must maintain two separate operational records:

1. Master Formulation Record (MFR)

The Master Formulation Record (MFR) serves as the pre-established protocol or "master recipe" for a CNSP. An MFR must be created for any non-sterile preparation compounded for multiple patients or when compounding from raw bulk active pharmaceutical ingredients (APIs). The MFR must include:

Official name, strength, dosage form, and physical description of the CNSP.

Complete list of all active and inactive ingredients with exact amounts, specifications, and raw material requirements.

Equipment and compounding tools required.

Explicit, step-by-step mixing and preparation instructions.

Assigned Beyond-Use Date (BUD) rationale and required storage conditions.

Detailed container-closure system specification.

Quality control procedures (e.g., pH evaluation, visual inspection, weight variation checks).

2. Compounding Record (CR)

The Compounding Record (CR) is the actual operational log completed during or immediately after the preparation of an individual prescription or batch. It documents the physical execution of the MFR for a specific patient. The CR must contain:

Name, strength, and dosage form of the CNSP, cross-referencing the specific MFR.

Internal lot/control number unique to the batch.

Names, lot numbers, and expiration dates of all raw ingredients used.

Exact weighed or measured quantities of each component.

Signatures or initials of the compounder and the supervising verifying pharmacist.

Date and time of preparation and final yield.

Assigned BUD and date of dispensing.

Results of quality control procedures.

Default Beyond-Use Dating (BUD) Limits (USP <795> Standards)

A critical distinction tested on the MPJE is the difference between an Expiration Date and a Beyond-Use Date (BUD) :

Expiration Date: Assigned by commercial drug manufacturers based on extensive stability testing in accordance with FDA regulations.

Beyond-Use Date (BUD): Assigned by the compounding pharmacist indicating the date or time after which a CNSP must not be used, stored, or transported. A BUD can NEVER exceed the expiration date of any individual API or raw material component used in the preparation.

In the absence of empirical, stability-indicating analytical testing for the specific formulation, pharmacists must strictly enforce the following USP <795> Default BUD Limits based on formulation type, presence of water, and storage condition:

1. Nonaqueous Formulations

Formulation Examples: Capsules, nonaqueous powders, nonaqueous ointments, nonaqueous pastes, nonaqueous suppositories, and oil-based liquids.

Maximum Assigned BUD: 180 days (6 months) or the earliest expiration date of any raw component, whichever is shorter.

Storage Requirement: Controlled room temperature (20°C to 25°C / 68°F to 77°F).

2. Water-Containing Oral Formulations

Formulation Examples: Aqueous oral solutions, oral suspensions, oral emulsions, oral gels, and aqueous oral syrups.

Maximum Assigned BUD: 14 days when stored under refrigeration.

Storage Requirement: Refrigerated conditions ( 2°C to 8°C / 36°F to 46°F ).

Rationale: Water provides an optimal environment for microbial proliferation and hydrolytic degradation. Cold storage retards microbial growth and chemical reaction rates.

3. Water-Containing Topical, Dermal & Mucosal Formulations

Formulation Examples: Aqueous creams, lotions, topical gels, mucosal sprays, nasal drops, and rectal/vaginal aqueous preparations.

Maximum Assigned BUD: 30 days .

Storage Requirement: Controlled room temperature (20°C to 25°C / 68°F to 77°F).

Summary Matrix: USP <795> Default Beyond-Use Dates

  • CNSP Formulation Type Water Presence Required Storage Condition Maximum Default BUD
  • Nonaqueous Formulations (Capsules, Powders, Oils) None Controlled Room Temp (20°C-25°C) 180 days (6 months)
  • Water-Containing Oral Formulations (Solutions, Suspensions) Yes Refrigerated ( 2°C to 8°C ) 14 days
  • Water-Containing Topical / Dermal (Creams, Lotions, Gels) Yes Controlled Room Temp (20°C-25°C) 30 days
  • Extending BUDs Beyond Default Limits

A pharmacist may assign an extended BUD exceeding the default limits ONLY IF :

The extension is supported by valid, published stability-indicating analytical study data for the exact formulation, container-closure, and storage condition, AND

For water-containing preparations, the formulation passes Antimicrobial Effectiveness Testing in accordance with USP <51> to ensure preservative efficacy.

Facility, Equipment & Sanitation Standards

Compounding Space: Compounding must occur in a dedicated, designated area with smooth, non-porous, cleanable surfaces (countertops, walls, flooring) resistant to chemical degradation.

Water Quality: Potable water must be available for hand washing. Purified Water (USP) or distilled water must be used for compounding formulations and final equipment rinsing.

Personal Hygiene & Garbing: Personnel must wash hands up to the elbows with soap and water before compounding. Clean aprons/gowns and disposable gloves are mandatory. Hair covers and face masks must be worn when compounding powders or hazardous non-sterile preparations.

Loading diagram... USP <795> Beyond-Use Date (BUD) Decision Tree